Nuwellis (NUWE) to Announce Earnings on Thursday

Nuwellis (NASDAQ:NUWE) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Nuwellis to announce earnings of ($23.80) per share and revenue of $2.4150 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:00 AM ET.

Nuwellis (NASDAQ:NUWE) last posted its earnings results on Tuesday, May 12th. The company reported ($73.15) earnings per share for the quarter, missing the consensus estimate of ($35.00) by ($38.15). The company had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $2.09 million. Nuwellis had a negative net margin of 214.90% and a negative return on equity of 32,351.83%.

Nuwellis Stock Up 4.2%

Shares of NUWE stock opened at $1.48 on Wednesday. The stock has a market cap of $2.75 million, a P/E ratio of -0.00 and a beta of 0.31. Nuwellis has a 52 week low of $1.34 and a 52 week high of $235.20. The company’s fifty day simple moving average is $3.75 and its two-hundred day simple moving average is $35.57.

Wall Street Analysts Forecast Growth

NUWE has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Nuwellis in a research report on Wednesday, June 24th. Wall Street Zen raised Nuwellis to a “hold” rating in a research note on Saturday, July 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.